NewLink Genetics Corp said it entered into an agreement withRoche Holding AG to develop NewLink’s cancer immunotherapy, making the Ebola vaccine developer eligible to receive over US$1 billion (RM3.27 billion) in milestone payments.
Immunotherapies are a class of drugs designed to help the body’s own immune system fend off disease.
02:12 Hotly Anticipated Google Fiber High-Speed Service Put on Hold as CEO Leaves50
16:36 AT&T, Time Warner poised to lobby lawmakers, regulators on proposed $85-billion merger16
12:23 Lockheed Martin's quarterly profit handily beats estimates13
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents14